ImmunoGen, Inc. Announces Webcast of Presentation at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference.CAMBRIDGE, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Susquehanna Financial Group's first annual SIGnificant Investment Options in Healthcare Conference will be webcast live. The presentation is scheduled to begin at 4:30 p.m. ET on March 1, 2007, and will be given at the Omni Berkshire Place hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . The presentation will provide an update on ImmunoGen. The webcast can be accessed through the "Investor Relations Investor relations The process by which the corporation communicates with its investors. " section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until March 8, 2007. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer . Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Companies licensing the right to develop anticancer compounds to specific targets using ImmunoGen's TAP technology include Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec , Biotest AG, Centocor (Johnson & Johnson), Genentech, and sanofi-aventis. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-MCC-DM1, in development by Genentech. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion